Jeffrey Humphrey is an oncologist, Chief Medical Officer and President of Kyowa Kirin Pharmaceutical Development Inc. (KKD) based in Princeton, New Jersey. KKD is the American/European drug subsidiary of Kyowa Hakko Kirin Company (KHK), a top-50 pharmaceutical company aspiring to become a Global Specialty Pharmaceutical company. As CMO/President, Jeff has oversight for US and European of experimental therapeutics for oncology, neurology, immunology, and a rare genetic disorder. KKD is developing 2 first-in- class KHK compounds that are approved in Japan for T-cell Leukemia and Parkinson’s disease, respectively. Dr.Humphrey is the first American president of KKD, a member of KHK’s senior R&D decision-making committee, and a member of the CEO’s executive committee.
Dr. Humphrey previously served as VP of Oncology at both Bristol-Myers Squibb and Bayer Pharmaceuticals, and Clinical Exploratory Head of Oncology at Pfizer. Dr. Humphrey’s work over the past 20 years has included oversight or direct involvement in of experimental and marketed oncology medicines, including submissions and/or launches of Sprycel, Ixempra, Yervoy, Erbitux, Nexavar, Ftorafur, and Taxol. He has developed specialized knowledge in anti-angiogenesis, companion diagnostics, and immuno-oncology during his career.
Dr. Humphrey holds an A.B., cum laude, from Harvard University in applied mathematics, anMD, Alpha Omega Alpha, from Case Western University School of Medicine, and completed his internal medicine internship and residency at the Johns Hopkins Hospital. Dr. Humphrey served as chief oncology fellow at the US NIH National Cancer Institute where he published original research in cell biology, biochemistry and molecular biology while completing fellowships in human medical genetics and medical oncology. Dr. Humphrey has co-authored multiple peer-reviewed publications, book chapters, and a patent, and has served as invited chairman and presenter at numerous academic and industry conferences.